CDNACareDx, Inc.
Price
+336%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, nothing alarming, price roughly fair, growing in the filings, the market undecided.
CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. We deliver solutions designed to empower clinicians and improve patient outcomes. The Company's integrated solutions include non-invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
CareDx, Inc. (CDNA) reported revenue of $132M in Q2 2026 (quarter ended Jun 30, 2026), up 52% from the same quarter a year earlier. That came with net income of $111M (84% of revenue). For the full year FY2025, revenue was $380M (+14% year on year) and net income −$21M. Its largest product in Q2 2026 was Service at $100M, 84% of the disclosed total, well ahead of Patient And Digital Solutions at 16%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 16, 2026On July 7, 2026, CareDx, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original 8-K”) with the Securities and Exchange Commission (the “SEC”) reporting the completion of its acquisition of Naveris, Inc., a Delaware corporation (“Naveris”)Acquisition or disposition completed · Form 8-K/A
- Jul 7, 2026Eurobio Transaction On June 30, 2026, CareDx, Inc. (the “Company”) completed the previously announced sale of the shares of CareDx AB, a wholly-owned Swedish subsidiary of the Company, and certain assets relating to the Company’s kitted laboratory products business and related software to Eurobio Scientific S.A. …Acquisition or disposition completed · Form 8-K
- Jun 15, 2026On June 11, 2026, CareDx, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $119.2MThe company’s own SEC segment disclosure.
- Service$99.9M84%
- Patient And Digital Solutions$19.2M16%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Diagnostics & Research
Ranks #5 of 21 by RyuScore